Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of topical AG013 for chemoradiation-induced oral mucositis in head and neck cancer
2016-004161-68Phase 2Completed
- Sponsor
- Oragenics, Inc.
- Start
- May 2018
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of dapatifagene navolactibac in stomatitis, sponsored by Oragenics, Inc.. Started May 2018; status: completed.
02
Drugs
dapatifagene navolactibac
03
Conditions
stomatitis
Beyond the preview
Go deeper on 2016-004161-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004161-68.